Evidence map›Paper›PMID 37789230›Full record

ArticleMedical oncology (Northwood, London, England)2023

Identification by molecular dynamic simulation and in vitro validation of SISB-A1, N-[1-(4-bromophenyl)-3-methyl-1H-pyrazol-5-yl]-2-[(2-oxo-4-phenyl-2H-chromen-7-yl) oxy], as an inhibitor of the Abl

Mesfer Al Shahrani, Reem M Gahtani, Mohammad Abohassan, Sultan Alasmari, Mohammed Makkawi

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mesfer Al ShahraniDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, P.O. Box 3665, 61481, Abha, Saudi Arabia.
Reem M GahtaniDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, P.O. Box 3665, 61481, Abha, Saudi Arabia.
Mohammad AbohassanDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, P.O. Box 3665, 61481, Abha, Saudi Arabia.
Sultan AlasmariDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, P.O. Box 3665, 61481, Abha, Saudi Arabia.
Mohammed MakkawiDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, P.O. Box 3665, 61481, Abha, Saudi Arabia. mmakkawi@kku.edu.sa.ORCID http://orcid.org/0000-0003-3901-7267
King Khalid University · SA

Funding

Deanship of Scientific Research, King Khalid University R.G.P.1/283/44
6 · The paper itself

Abstract

The discovery of imatinib, a specific inhibitor of Abl kinase, revolutionized the therapeutic approach to chronic myeloid leukemia (CML); however, its efficacy can be impeded by the emergence of novel mutations within the kinase domain, particularly Abl

Indexed as

Fusion Proteins, bcr-ablLeukemia, Myelogenous, Chronic, BCR-ABL PositiveDrug Resistance, NeoplasmHumansImatinib MesylateMolecular Dynamics SimulationMutationOxotremorineProtein Kinase InhibitorsFusion Proteins, bcr-ablImatinib MesylateN-methylacetamide-oxotremorine MOxotremorineProtein Kinase InhibitorsAblT315I kinase mutationChronic myeloid leukemia (CML)ImatinibMolecular dynamic simulationPonatinib

Identifiers

PMID37789230
OpenAlexW4387300494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.